Compare UPLD & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPLD | NXL |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | 760 | 8 |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 10.6M |
| IPO Year | 2014 | N/A |
| Metric | UPLD | NXL |
|---|---|---|
| Price | $4.45 | $0.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.75 | N/A |
| AVG Volume (30 Days) | 15.4K | ★ 259.2K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.38 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,767,000.00 | N/A |
| Revenue This Year | N/A | $15.52 |
| Revenue Next Year | $1.95 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $0.50 | $0.31 |
| 52 Week High | $6.65 | $2.00 |
| Indicator | UPLD | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 43.76 |
| Support Level | $4.01 | $0.35 |
| Resistance Level | $5.65 | $0.49 |
| Average True Range (ATR) | 0.39 | 0.04 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 22.71 | 22.73 |
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels. Geographically, the company has operations in the U.S., United Kingdom and Canada, of which United States derives maximum revenue.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the US and China, with China generating the maximum sales.